March 31, 2023 07:13 AM EDTUpdated 09:17 AM
Peer Review

Jim Mullen scours pri­vate eq­ui­ty deals amid biotech win­ter; Ex-Ab­b­Vie med­ical chief suc­ceeds Brig­gs Mor­ri­son at Syn­dax

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Amber Tong

Jim Mullen is in, by his count, his third or fourth “long, cold win­ter in biotech in­vest­ing.” But that’s not stop­ping the ex-Bio­gen CEO from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times